Lung cancer is the leading cause of cancer deaths worldwide, mainly because it gets detected late. The discovery by the ...

Approximately 40.5 percent of Americans will be diagnosed with cancer at some point in their life. It’s a diagnosis no ...

The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...

BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

A recent analysis shows that additional invasive staging modalities lead to relevant changes in target volume in some ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

Economic Toxicity, Lung Cancer, Multi-Center Trial, Correlation Analysis Share and Cite: Mao, R.M. and Peng, L.Y. (2025) Multi-Center Investigation on the Level of Economic Toxicity in Patients with ...

Chen, F. (2025) Advances in the Application of Deep Learning in Prognostic Models for Non-Small Cell Lung Cancer. Health, 17, ...

The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

A study reveals how cancer disrupts RNA splicing and presents a potential therapy using antisense oligonucleotides to target ...

The safety profile for Imfinzi was generally manageable and consistent with the known profile of this medicine.